nach oben

Erschienen in:

01.04.2014 | Original article

Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma

Final report of a pilot study

verfasst von: M. Balducci, B. Diletto, S. Chiesa, G.R. D’Agostino, M.A. Gambacorta, M. Ferro, C. Colosimo, G. Maira, C. Anile, V. Valentini

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Backgroud

Evaluated in this study were the feasibility and the efficacy of concurrent low dose fractionated radiotherapy (LD-FRT) and chemotherapy as palliative treatment for recurrent/progressive glioblastoma multiforme (GBM).

Patients and methods

Eligible patients had recurrent or progressive GBM, Karnofsky performance status ≥ 70, prior surgery, and standard radiochemotherapy treatment. Recurrence/progression disease during temozolomide (TMZ) received cisplatin (CDDP; 30 mg/m² on days 1, 8, 15), fotemustine (FTM; 40 mg/m² on days 2, 9, 16), and concurrent LD-FRT (0.3 Gy twice daily); recurrence/progression after 4 months from the end of adjuvant TMZ were treated by TMZ (150/200 mg/m² on days 1–5) concomitant with LD-FRT (0.4 Gy twice daily). Primary endpoints were safety and toxicity.

Results

A total of 32 patients were enrolled. Hematologic toxicity G1–2 was observed in 18.7 % of patients and G3–4 in 9.4 %. One patient (3.1 %) had complete response, 3 (9.4 %) had partial response, 8 (25 %) had stable disease for at least 8 weeks, while 20 patients (62.5 %) experienced progressive disease. The clinical benefit was 37.5 %. Median progression-free survival (PFS) and overall survival (OS) were 5 and 8 months, respectively. Survival rate at 12 months was of 27.8 %.

Conclusion

LD-FRT and chemotherapy for recurrent/progressive GBM have a good toxicity profile and clinical outcomes, even though further investigation of this novel palliative treatment approach is warranted.

Guckenberger M, Mayer M, Buttmann M et al (2011) Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlenther Onkol 187(9):548–554PubMedCrossRef

Lang O, Liebermeister E, Liesegang J, Sautter-Bihl ML (1998) Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 174(12):629–632PubMedCrossRef

American Cancer Society (2008) Cancer facts & figures 2008. American Cancer Society, Atlanta

Stupp R, Mason WP, Bent MJ van den et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

Jansen EP, Dewit LG, Herk M van, Bartelink H (2000) Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 56(2):151–156PubMedCrossRef

Wallner KE, Galicich JH, Krol G et al (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16(6):1405–1409PubMedCrossRef

Chamberlain MC, Kormanik PA (1998) Practical guidelines for the treatment of malignant gliomas. West J Med 168(2):114–120PubMedCentralPubMed

Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729PubMedCrossRef

Tselis N, Kolotas C, Birn G et al (2007) CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol 183(10):563–570PubMedCrossRef

10.

Henke G, Paulsen F, Steinbach JP et al (2009) Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 185(2):113–119PubMedCrossRef

11.

Fokas E, Wacker U, Gross MW (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185(4):235–240PubMedCrossRef

12.

Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trial. J Clin Oncol 17:2572–2578PubMed

13.

Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CC1-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 23:5294–5304PubMedCrossRef

14.

Niyazi M, Siefert A, Schwarz SB et al (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98(1):1–14PubMedCrossRef

15.

Perry JR, Rizek P, Cashman R et al (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 113(8):2152–2157PubMedCrossRef

16.

Short SC, Mitchell SA, Boulton P et al (1999) The response of human glioma cell lines to low-dose radiation exposure. Int J Radiat Biol 75:1341–1348PubMedCrossRef

17.

Short S, Mayes C, Woodcock M et al (1999) Low-dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol 75:847–855PubMedCrossRef

18.

Beauchesne PD, Bertrand S, Branche R et al (2003) Human malignant glioma cell lines are sensitive to low radiation doses. Int J Cancer 105:33–40PubMedCrossRef

19.

Krause M, Wohlfarth J, Georgi B et al (2005) Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol 81(10):751–758PubMedCrossRef

20.

Chendil D, Oakes R, Alcock RA et al (2000) Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer 89:1893–1900PubMedCrossRef

21.

Short SC, Kelly J, Mayes CR et al (2001) Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol 77:655–664PubMedCrossRef

22.

Dey S, Spring PM, Arnold S et al (2003) Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 9:1557–1565PubMed

23.

Gupta S, Arnold AM, Spring P et al (2004) Low-dose fractionated radiation potentiates the effect of cisplatin independent of the hyper-radiation sensitivity phenomenon in human lung cancer cell lines [Abstract]. Proc Am Assoc Cancer Res 45

24.

Arnold SM, Regine WF, Ahmed MM et al (2004) Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 58:1411–1417PubMedCrossRef

25.

Spring PM, Arnold SM, Shajahan S et al (2004) Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck. Cell Cycle 3:479–485PubMedCrossRef

26.

Regine WF, Hanna N, Garofalo MC et al (2007) Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys 68(1):172–177PubMedCrossRef

27.

Simpson L, Galanis E (2006) Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 6(11):1593–1607PubMedCrossRef

28.

Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779–4786PubMedCrossRef

29.

Franceschi E, Omuro AM, Lassman AB et al (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476PubMedCrossRef

30.

Meulemans A, Giroux B, Hannoun P et al (1991) Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy 37:86–92PubMedCrossRef

31.

Fischel JL, Formento P, Etienne MC, Gioanni J et al (1990) In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol 25:337–341PubMedCrossRef

32.

Fabrini MG, Silvano G, Lolli I et al (2009) A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92(1):79–86PubMedCrossRef

33.

Scoccianti S, Detti B, Sardaro A et al (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19(6):613–620PubMedCrossRef

34.

De Wit MC, Bruin HG de, Eijkenboom W et al (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3):535–537CrossRef

35.

Emami B, Lyman j, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedCrossRef

36.

Lawrence YR, Li XA, Naqa I el et al (2010) Radiation dose–volume effects in the brain. Int J Radiat Oncol Biol Phys 76(3 Suppl):S20–S27PubMedCentralPubMedCrossRef

37.

Balducci M, D’Agostino GR, Manfrida S et al (2010) Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. J Neurooncol 97(1):95–100PubMedCrossRef

38.

De Bonis P, Anile C, Pompucci A et al (2012) Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir (Wien) 154(8):1371–1378

39.

Rodier JM, Da Costa L, Adams D et al (1996) Fotemustine and cisplatin association in patients with recurrent malignant glioma. Proc Am Sol Clin

40.

Lambin P, Malaise EP, Joiner MC (1994) The effect of very low radiation doses on the human bludder cell line RT112. Radiother Oncol 32:63–72PubMedCrossRef

41.

Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v4.0. ctep.cancer.gov/reporting/ctc.html. Accessed 29. Dec 2013

42.

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed

43.

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2008 (Revised March 23, 2012). http://www.cbtrus.org/reports/reports.html. Accessed 29. Dec 2013

44.

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef

45.

Taghian A, Ramsay J, Allalunis-Turner J et al (1993) Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 25(2):243–249PubMedCrossRef

46.

Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cells—potential partners in glioma drug resistance? Cancer Treat Rev 34(6):558–567PubMedCrossRef

47.

Lowe SW, Ruley HE, Jacks T, Housman DE et al (1993) P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967PubMedCrossRef

48.

Benjamin B, David C, Dieter L et al (2010) Defective p53 antiangiogenic signaling in glioblastoma. Neuro Oncol 12(9):894–907CrossRef

49.

Nieder C, Adam M, Molls M, Grosu AL (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60(3):181–193PubMedCrossRef

50.

Franceschi E, Tosoni A, Bartolini S et al (2009) Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther 9(5):613–619PubMedCrossRef

51.

Lin SH, Kleinberg LR (2008) Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8(3):343–359PubMedCrossRef

52.

Attenello FJ, Mukherjee D, Datoo G et al (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15(10):2887–2893PubMedCrossRef

53.

Hart MG, Grant R, Garside R et al (2008) Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev 3:CD007294PubMed

54.

Gilbert MR (2011) Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. Semin Oncol 38(Suppl 4):S21–S33PubMedCrossRef

55.

Marples B, Wouters BG, Collis SJ et al (2004) Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiationdamaged G2-phase cells. Radiat Res 161:247–255PubMedCrossRef

56.

Enns L, Bogen KT, Wizniak J et al (2004) Low- dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res 2(10):557–566PubMed

57.

Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155–1160PubMedCentralPubMedCrossRef

58.

Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266PubMedCrossRef

59.

Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with Glioblastoma multiforme at first relapse. Br J Cancer 83:588–593PubMedCentralPubMedCrossRef

60.

Wick W, Steinbach JP, Kuker WM et al (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115PubMedCrossRef

61.

Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361PubMedCrossRef

62.

Joiner MC, Denekamp J, Maughan RL (1986) The use of ‘top-up’ experiments to investigate the effect of very small doses per fraction in mouse skin. Int J Radiat Biol Relat Stud Phys Chem Med 49:565–580PubMedCrossRef

63.

Joiner MC, Johns H (1988) Renal damage in the mouse: the response to very small doses per fraction. Radiat Res 114:385–398PubMedCrossRef

64.

Turesson I, Nyman J, Qvarnström F et al (2010) A low-dose hypersensitive keratinocyte loss in response to fractionated radiotherapy is associated with growth arrest and apoptosis. Radiother Oncol 94(1):90–101PubMedCrossRef

65.

Rachidi W, Harfourche G, Lemaitre G et al (2007) Sensing radiosensitivity of human epidermal stem cells. Radiother Oncol 83(3):267–276PubMedCrossRef

66.

Gay H (2010) Role of the linear-quadratic model in high doses per fraction. Radiother Oncol 94(1):122–123CrossRef

67.

Courdi A (2010) High doses per fraction and the linear-quadratic model. Radiother Oncol 94(1):121–122PubMedCrossRef

68.

Short SC, Woodcock M, Marples B, Joiner MC et al (2003) Effects of cell cycle phase on low-dose hyper-radiosensitivity. Int J Radiat Biol 79(2):99–105PubMedCrossRef

69.

Beauchesne P, Bernier V, Carnin C et al (2010) Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro Oncol 12(6):595–602PubMedCentralPubMedCrossRef

70.

Valentini V, Massaccesi M, Balducci M et al (2010) Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? Int J Radiat Oncol Biol Phys 76:535–539PubMedCrossRef

71.

Mantini G, Valentini V, Meduri B et al (2102) Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: A prospective phase II study. Radiother Oncol 105:161–166CrossRef

72.

Balducci M, Chiesa S, Diletto B et al (2012) Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 14:79–86PubMedCentralPubMedCrossRef

Titel: Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma
Final report of a pilot study
verfasst von: M. Balducci
B. Diletto
S. Chiesa
G.R. D’Agostino
M.A. Gambacorta
M. Ferro
C. Colosimo
G. Maira
C. Anile
V. Valentini
Publikationsdatum: 01.04.2014
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0506-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma

Final report of a pilot study

Abstract

Backgroud

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Backgroud

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Predicting the presence of extracranial metastases in patients with brain metastases upon first diagnosis of cancer

Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy

Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation

DEGRO practical guidelines: radiotherapy of breast cancer III—radiotherapy of the lymphatic pathways

Intraoperative Teilbrustbestrahlung mit Elektronen versus konventionelle externe Ganzbrustbrustbestrahlung beim frühen Mammakarzinom

Temozolomide-induced liver damage

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie